Global Oncolytic Virus Therapy Market and Pipeline Report Published by KuicK Research

Release Date: 20-Apr-2017

“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic virus therapy in clinical trials are in preclinical phase followed by Phase-I trials

For Report Sample Contact :neeraj@kuickresearch.com

"Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022" Report Table of Contents (190 Page)

1. Prologue to Oncolytic Virus

1.1 Outline of Oncolytic Virotherapy

1.2 Trail from Genesis to Biogenetics

2. Primer of Virotherapy in Malignancies

2.1 Oncolytic Viruses towards Cancer

2.2 Approaches for Targeting Tumor Cells

2.2.1 Pro Apoptotic Targeting

2.2.2 Translational Targeting

2.2.3 Transcriptional Targeting

2.2.4 Transductional Targeting

3. Mechanism Involved in Viral Oncolysis

3.1 Viral Entry into Cancerous Cells

3.2 Efficacy Routes Followed by Oncogenic Viruses

3.3 Mechanism of Tumor Specificity

3.3.1 Defective Anti-Viral Responses

3.3.2 Receptor Targeting for Tumor Selective Intake

3.3.3 Targeting to Tumor Specific Promoters

3.3.4 Viral Gene Deletions

3.3.5 Proteolytic Processing of Virus Particles in Tumor Microenvironment

4. Cancer Immunotherapy by Oncolytic Viruses

4.1 Stimulation of Antitumor Immune Responses

4.2 Oncolytic Viruses as Cancer Vaccines

5. Varieties of Viruses Casted as Oncolytic Viruses

5.1 Oncolytic Wild Type Viruses

5.1.1 Reovirus (Respiratory Enteric Orphan Virus)

5.1.2 Vesicular Stomatitis Virus (VSV)

5.1.3 Newcastle Disease Virus (NDV)

5.1.4 Myxoma

5.2 Genetically Engineered Oncolytic Viruses

5.2.1 Adenoviruses

5.2.2 Herpes Simplex Virus

5.2.3 Vaccinia Virus

6. Approved Oncolytic Virus Therapeutics

6.1 Onxy-15

6.2 RIGVIR

6.3 Talimogene laherparepvec (T-VEC)

6.4 Reolysin

7. Potential Oncolytic Viruses for Cancers

7.1 Breast Cancer

7.2 Lung Cancer

7.3 Prostate Cancer

7.4 Melanoma

7.5 Brain Tumor

7.6 Blood Cancer

8. Global Oncolytic Virus Therapy Market Overview

8.1 Preface towards Oncolytic Virus Arcade

8.2 Market Aspects of Approved Oncolytic Viruses

8.3 Oncolytic Virus Clinical Pipeline Overview

9. Oncolytic Virus Market Dynamics

9.1 Accelerative Parameters

9.2 Major Challenges Faced by Oncolytic Virus

10. Future Aspects of Oncolytic Viral Therapy

11. Global Oncolytic Virus Clinical Pipeline by Company, Indication and Phase

11.1 Research

11.2 Preclinical

11.3 Phase-I

11.4 Phase-I/II

11.5 Phase-II

11.6 Phase-II/III

11.7 Phase-III

12. Marketed Oncolytic Virus Clinical Insight by Company and Indication

12.1 Talimogene Laherparepvec

12.2 H 101

13. No Development Reported Oncolytic Virus Clinical Insight by Company, Indication and Phase

Global Oncolytic Virus Therapy Market and Pipeline Report Published by KuicK Research

For Report Sample Contact :neeraj@kuickresearch.com

"Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022" Report Table of Contents (190 Page)

1. Prologue to Oncolytic Virus

1.1 Outline of Oncolytic Virotherapy

1.2 Trail from Genesis to Biogenetics

2. Primer of Virotherapy in Malignancies

2.1 Oncolytic Viruses towards Cancer

2.2 Approaches for Targeting Tumor Cells

2.2.1 Pro Apoptotic Targeting

2.2.2 Translational Targeting

2.2.3 Transcriptional Targeting

2.2.4 Transductional Targeting

3. Mechanism Involved in Viral Oncolysis

3.1 Viral Entry into Cancerous Cells

3.2 Efficacy Routes Followed by Oncogenic Viruses

3.3 Mechanism of Tumor Specificity

3.3.1 Defective Anti-Viral Responses

3.3.2 Receptor Targeting for Tumor Selective Intake

3.3.3 Targeting to Tumor Specific Promoters

3.3.4 Viral Gene Deletions

3.3.5 Proteolytic Processing of Virus Particles in Tumor Microenvironment

4. Cancer Immunotherapy by Oncolytic Viruses

4.1 Stimulation of Antitumor Immune Responses

4.2 Oncolytic Viruses as Cancer Vaccines

5. Varieties of Viruses Casted as Oncolytic Viruses

5.1 Oncolytic Wild Type Viruses

5.1.1 Reovirus (Respiratory Enteric Orphan Virus)

5.1.2 Vesicular Stomatitis Virus (VSV)

5.1.3 Newcastle Disease Virus (NDV)

5.1.4 Myxoma

5.2 Genetically Engineered Oncolytic Viruses

5.2.1 Adenoviruses

5.2.2 Herpes Simplex Virus

5.2.3 Vaccinia Virus

6. Approved Oncolytic Virus Therapeutics

6.1 Onxy-15

6.2 RIGVIR

6.3 Talimogene laherparepvec (T-VEC)

6.4 Reolysin

7. Potential Oncolytic Viruses for Cancers

7.1 Breast Cancer

7.2 Lung Cancer

7.3 Prostate Cancer

7.4 Melanoma

7.5 Brain Tumor

7.6 Blood Cancer

8. Global Oncolytic Virus Therapy Market Overview

8.1 Preface towards Oncolytic Virus Arcade

8.2 Market Aspects of Approved Oncolytic Viruses

8.3 Oncolytic Virus Clinical Pipeline Overview

9. Oncolytic Virus Market Dynamics

9.1 Accelerative Parameters

9.2 Major Challenges Faced by Oncolytic Virus

10. Future Aspects of Oncolytic Viral Therapy

11. Global Oncolytic Virus Clinical Pipeline by Company, Indication and Phase

11.1 Research

11.2 Preclinical

11.3 Phase-I

11.4 Phase-I/II

11.5 Phase-II

11.6 Phase-II/III

11.7 Phase-III

12. Marketed Oncolytic Virus Clinical Insight by Company and Indication

12.1 Talimogene Laherparepvec

12.2 H 101

13. No Development Reported Oncolytic Virus Clinical Insight by Company, Indication and Phase

13.1 No Development Reported

13.2 Discontinued

14. Competitive Landscape

14.1 BioVex

14.2 Cell Genesys

14.3 Crusade Laboratories

14.4 Genelux Corporation

14.5 Jennerex Biotherapeutics

14.6 Lokon Pharma

14.7 Merck

14.8 MultiVir

14.9 Oncolys BioPharma

14.10 Oncolytics Biotech